BCL6

B-cell lymphoma 6 protein

21,807 patent compounds predicted against BCL6, 12,870 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL655635	0.80	12/20
SCHEMBL2103262	0.80	12/20
SCHEMBL2100643	0.72	12/20
SCHEMBL2101082	0.72	12/20
SCHEMBL2102179	0.72	12/20
SCHEMBL2102001	0.71	12/20
SCHEMBL2102021	0.71	12/20
SCHEMBL658038	0.71	12/20
SCHEMBL2101829	0.67	12/20
SCHEMBL2102227	0.67	12/20
SCHEMBL2102590	0.66	12/20
SCHEMBL1743271	0.66	12/20
SCHEMBL2103076	0.65	12/20
SCHEMBL2103083	0.65	12/20
SCHEMBL2103092	0.65	12/20
SCHEMBL2102596	0.64	12/20
SCHEMBL2100762	0.64	12/20
SCHEMBL1474421	0.63	12/20
SCHEMBL2100766	0.62	12/20
SCHEMBL2102228	0.62	12/20

Germline variants in BCL6 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full BCL6 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to BCL6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma	PHASE4	NOT_YET_RECRUITING
Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients	PHASE3	UNKNOWN
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma	PHASE2	RECRUITING
Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients	PHASE2	COMPLETED
DALY II Japan/MB-CART2019.1 for DLBCL	PHASE2	RECRUITING
The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL	PHASE2	ACTIVE_NOT_RECRUITING
Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma	PHASE1/PHASE2	WITHDRAWN
A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression	PHASE2	UNKNOWN
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders	PHASE1/PHASE2	COMPLETED
A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations	PHASE2	ACTIVE_NOT_RECRUITING
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma	PHASE1/PHASE2	RECRUITING
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma	PHASE1/PHASE2	RECRUITING
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies	PHASE2	COMPLETED
CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma	PHASE1/PHASE2	COMPLETED
Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA	PHASE1	RECRUITING
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma	PHASE1	COMPLETED
Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma	PHASE1	UNKNOWN
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma	PHASE1	COMPLETED
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies	PHASE1	ACTIVE_NOT_RECRUITING
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)	EARLY_PHASE1	RECRUITING
Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma	nan	NOT_YET_RECRUITING
A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma	nan	RECRUITING
Proof of Concept for Real-time Multicentric Monitoring of MRD by PET and ctDNA in Aggressive B-Cell Lymphomas	nan	NOT_YET_RECRUITING
BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.	nan	UNKNOWN
Anti CD19 Gene Therapy for B-cell Lymphoma	nan	RECRUITING
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma	nan	COMPLETED
Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.	nan	COMPLETED
Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)	nan	RECRUITING
Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma	nan	RECRUITING
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a BCL6 binder may also engage these)

Protein	Name	Similarity
P41183	—	1.000	P41183 →
Q5ZM39	—	1.000	Q5ZM39 →
Q9JKY3	—	1.000	Q9JKY3 →
Q3SWU4	—	0.995	Q3SWU4 →
Q8BXX2	—	0.995	Q8BXX2 →
Q9GZV8	—	0.995	Q9GZV8 →
Q8R0A2	—	0.994	Q8R0A2 →
Q7ZWZ4	—	0.994	Q7ZWZ4 →
Q0IJ29	—	0.994	Q0IJ29 →
Q99592	—	0.993	Q99592 →
Q6NRM8	—	0.993	Q6NRM8 →
A0JN76	—	0.993	A0JN76 →
Q6NRM0	—	0.993	Q6NRM0 →
Q7TQG0	—	0.993	Q7TQG0 →
Q0P4X6	—	0.993	Q0P4X6 →
O95625	—	0.992	O95625 →
P46200	—	0.992	P46200 →
O75626	—	0.992	O75626 →
Q6ZSB9	—	0.992	Q6ZSB9 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.992	landscape →
G5E8B9	—	0.992	G5E8B9 →
Q8NCP5	—	0.992	Q8NCP5 →
Q64318	—	0.992	Q64318 →
P14404	—	0.992	P14404 →
Q9WUK6	—	0.992	Q9WUK6 →
Q0P4W9	—	0.992	Q0P4W9 →
Q1L8W0	—	0.992	Q1L8W0 →
Q76I79	—	0.992	Q76I79 →
Q80WT2	—	0.991	Q80WT2 →
A1L2U9	—	0.991	A1L2U9 →